Avalo Therapeutics, Inc. (AVTX)

10.85 -0.64 (-5.57%) 收市：04:00PM EDT

Avalo Therapeutics, Inc.

540 Gaither Road
Suite 400
Rockville, MD 20850
United States
410-522-8707
https://www.avalotx.com

版塊: Healthcare
行業: Biotechnology
全職員工: 19

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Garry A. Neil M.D.	Chairman of the Board, President & CEO	475k	無	1954
Mr. Christopher Ryan Sullivan	CFO & Head of Investor relations	350k	無	1984
Dr. Solomon H. Snyder M.D.	Founder and Chairman of Scientific Advisory Board	無	無	1939
Dr. Barbara S. Slusher Ph.D.	Founder and Member of Scientific Advisory Board	無	無	1965
Dr. Lisa Hegg Ph.D.	Senior Vice President of Program Management, Corporate Infrastructure & Clinical Operations	無	無	無
Ms. Colleen Matkowski	Senior Vice President of Global Regulatory Affairs & Quality Assurance	無	無	無
Dr. Dino C. Miano Ph.D.	Senior Vice President of CMC & Technical Operations	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

公司管治

截至 無 止，Avalo Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。